Administration of protegrin peptide IB-367 to prevent endotoxin induced mortality in bile duct ligated rats

Gut. 2003 Jun;52(6):874-8. doi: 10.1136/gut.52.6.874.

Abstract

Background: Postoperative morbidity in patients with obstructive jaundice remains high because of increased susceptibility to endotoxin and the inflammatory cascade.

Aims: An experimental study was designed to investigate the efficacy of protegrin peptide IB-367, an antimicrobial positively charged peptide, in neutralising Escherichia coli 0111:B4 lipopolysaccharide (LPS) in bile duct ligated rats.

Methods: Adult male Wistar rats were injected intraperitoneally with 2 mg/kg E coli 0111:B4 LPS one week after sham operation or bile duct ligation (BDL). Six groups were studied: sham with placebo, sham with 120 mg/kg tazobactam-piperacillin (TZP), sham with 1 mg/kg IB-367, BDL with placebo, BDL with 120 mg/kg TZP, and BDL with 1 mg/kg IB-367.

Results: Main outcome measures were: endotoxin and tumour necrosis factor alpha (TNF-alpha) concentrations in plasma, evidence of bacterial translocation in blood and peritoneum, and lethality. After LPS, TNF-alpha plasma levels were significantly higher in BDL rats compared with sham operated animals. IB-367 caused a significant reduction in plasma endotoxin and TNF-alpha concentrations compared with placebo and TZP treated groups. In contrast, both TZP and IB-367 significantly reduced bacterial growth compared with saline treatment. Finally, LPS induced 60% and 55% lethality in BDL placebo and TZP treated rats and no lethality in sham operated rats, while only IB-367 significantly reduced lethality to 10%.

Conclusions: By virtue of its dual antimicrobial and antiendotoxin properties, IB-367 could be an interesting compound to inhibit bacterial translocation and endotoxin release in obstructive jaundice.

MeSH terms

  • Animals
  • Anti-Infective Agents / therapeutic use
  • Antimicrobial Cationic Peptides
  • Bacterial Translocation / drug effects
  • Bile Ducts / surgery
  • Cholestasis / surgery*
  • Disease Models, Animal
  • Endotoxemia / prevention & control*
  • Escherichia coli Infections / prevention & control*
  • Ligation
  • Lipopolysaccharides / toxicity
  • Male
  • Peptides
  • Postoperative Complications / prevention & control*
  • Proteins / therapeutic use*
  • Rats
  • Rats, Wistar
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Anti-Infective Agents
  • Antimicrobial Cationic Peptides
  • Lipopolysaccharides
  • Peptides
  • Proteins
  • Tumor Necrosis Factor-alpha
  • lipopolysaccharide, Escherichia coli O111 B4
  • antimicrobial peptide IB-367